Michail Ignatiadis, Director of Breast Medical Oncology Clinic and Program at Institut Jules Bordet, shared on LinkedIn:
“It was truly energizing to moderate this session and the stimulating discussion that followed with outstanding colleagues:
- Fatima Cardoso,
- Antonio Giordano,
- Hadar Goldvaser,
- Ingrid Mayer.
Precision medicine is already here, improving outcomes for our patients with ER+ metastatic breast cancer!
Many challenges remain, but also exciting opportunities as we move towards truly personalized treatment for every patient.
Thank you OncoDaily for hosting us!”
To which, Hadar Goldvaser, Associate Professor of Medicine at the Hebrew University of Jerusalem, added:
“Thank you, Michail Ignatiadis and OncoDaily, for the opportunity to be part of this stimulating discussion!
A pleasure to exchange ideas with such outstanding colleagues.”
You can also read: MAMMÔ 2026 Day 2 Highlights: From Adjuvant Optimization to Metastatic Breast Cancer, ADCs and Precision Treatment
